193 related articles for article (PubMed ID: 32062835)
1. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus.
Vázquez Estévez S; Anido U; Lázaro M; Fernández O; Fernández Núñez N; de Dios Álvarez N; Varela V; Campos Balea B; Agraso S; Areses MC; Iglesias L; Blanco M; Maciá S; Anton Aparicio LM
Clin Transl Oncol; 2020 Sep; 22(9):1565-1579. PubMed ID: 32062835
[TBL] [Abstract][Full Text] [Related]
2. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma.
Cowey CL
Drug Des Devel Ther; 2013; 7():519-27. PubMed ID: 23818763
[TBL] [Abstract][Full Text] [Related]
3. Tivozanib: a new treatment option for renal cell carcinoma.
Saes L; Eskens FALM
Drugs Today (Barc); 2017 Nov; 53(11):609-618. PubMed ID: 29451277
[TBL] [Abstract][Full Text] [Related]
4. Tivozanib: First Global Approval.
Kim ES
Drugs; 2017 Nov; 77(17):1917-1923. PubMed ID: 28971328
[TBL] [Abstract][Full Text] [Related]
5. The role of tivozanib in advanced renal cell carcinoma therapy.
Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
[TBL] [Abstract][Full Text] [Related]
6. Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.
Jacob A; Shook J; Hutson TE
Future Oncol; 2020 Oct; 16(28):2147-2164. PubMed ID: 32692256
[TBL] [Abstract][Full Text] [Related]
7. Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
Wright KM
Oncology (Williston Park); 2020 Jul; 34(7):257. PubMed ID: 32674211
[TBL] [Abstract][Full Text] [Related]
8. Tivozanib for the treatment of renal cell carcinoma.
Santoni M; Massari F; Piva F; Carrozza F; Di Nunno V; Cimadamore A; Martignetti A; Montironi R; Battelli N
Expert Opin Pharmacother; 2018 Jun; 19(9):1021-1025. PubMed ID: 29851529
[TBL] [Abstract][Full Text] [Related]
9. Tivozanib for the treatment of metastatic renal cancer.
Wong HH; Eisen T
Expert Rev Anticancer Ther; 2013 Jun; 13(6):649-60. PubMed ID: 23773100
[TBL] [Abstract][Full Text] [Related]
10. Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
Gupta S; Fishman M
Expert Opin Pharmacother; 2011 Dec; 12(18):2915-22. PubMed ID: 22098229
[TBL] [Abstract][Full Text] [Related]
11. Tivozanib: practical implications for renal cell carcinoma and other solid tumors.
Berge EM; Bowles DW; Flaig TW; Lam ET; Jimeno A
Drugs Today (Barc); 2013 May; 49(5):303-15. PubMed ID: 23724410
[TBL] [Abstract][Full Text] [Related]
12. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
Mehta A; Sonpavde G; Escudier B
Future Oncol; 2014 Aug; 10(11):1819-26. PubMed ID: 25325825
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Basso U; Procopio G; Fornarini G; Massari F; Bearz A; Fratino L; Milella M; Bassanelli M; Ermacora P; Bimbatti D; Verzoni E; Rizzo M; Porta C
Oncology; 2021; 99(12):747-755. PubMed ID: 34583356
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis.
Manz KM; Fenchel K; Eilers A; Morgan J; Wittling K; Dempke WCM
Adv Ther; 2020 Feb; 37(2):730-744. PubMed ID: 31838709
[TBL] [Abstract][Full Text] [Related]
15. Tivozanib: A New Hope for Treating Renal Cell Carcinoma.
Passi I; Billowria K; Kumar B; Chawla PA
Anticancer Agents Med Chem; 2023; 23(5):562-570. PubMed ID: 35718972
[TBL] [Abstract][Full Text] [Related]
16. Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.
Procopio G; Pignata S; Altavilla A; Attademo L; De Lisi D; Verzoni E; De Giorgi U; Santini D
Future Oncol; 2019 Aug; 15(22):2657-2666. PubMed ID: 31339065
[TBL] [Abstract][Full Text] [Related]
17. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Fogli S; Porta C; Del Re M; Crucitta S; Gianfilippo G; Danesi R; Rini BI; Schmidinger M
Cancer Treat Rev; 2020 Mar; 84():101966. PubMed ID: 32044644
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
19. Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval.
Viray H; McDermott DF; Einstein DJ
Expert Rev Anticancer Ther; 2022 Jul; 22(7):695-702. PubMed ID: 35698870
[TBL] [Abstract][Full Text] [Related]
20. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
